Detail akcie Viking Therapeut online

Business Summary: Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company that is focused on the development of therapies for the treatment of metabolic and endocrine disorders. Its clinical programs include VK2735, a novel dual agonist of the glucagon-like peptide 1 and glucose-dependent insulinotropic polypeptide receptors for the potential treatment of various metabolic disorders. It is evaluating an oral formulation of VK2735 in a Phase II trial. It is also developing VK2809, a novel, orally available, small molecule selective thyroid hormone receptor beta agonist for the treatment of lipid and metabolic disorders. Its newest program is evaluating a series of internally developed dual amylin and calcitonin receptor agonists for the treatment of obesity and other metabolic disorders. In the rare disease space, it is developing VK0214, a novel, orally available, small molecule selective thyroid hormone receptor beta agonist for the potential treatment of X-linked adrenoleukodystrophy.
Financial Summary: BRIEF: For the fiscal year ended 31 December 2025, Viking Therapeutics Inc revenues was not reported. Net loss increased from $110M to $359.6M. Higher net loss reflects Drug development segment loss increase from $150.9M to $393.3M. Basic Earnings per Share excluding Extraordinary Items decreased from -$1.01 to -$3.19.